Polycystic Ovarian Syndrome (PCOS) Treatment Market Analysis By Drugs (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants, Anti-obesity), By Surgery, And Segment Forecasts, 2018 - 2025

Industry Insights

The global polycystic ovarian syndrome treatment market size was valued at USD 3.3 billion in 2016 and is expected to grow at a CAGR of 5.0% over the forecast period. According to the research conducted by American Academy of Family Physicians, approximately 7% women of reproductive age are affected by Polycystic Ovary Syndrome (PCOS) in the U.S.

Presently, no specific drug for this condition is commercially available. Thus, treating symptoms of the disorder is the prime aim of the treatment regimen. This syndrome has a wide range of symptoms due to which a range of drug class/combinations are used in therapeutics. Therefore, market leaders are aiming to develop a specific drug/treatment to cure the root cause of this disease. AstraZeneca is one of the leaders involved in developing such a drug.

Drug Class Insights

PCOS is a genetic disorder that passes from one generation to another in a family, which leads to a high incidence of this condition across the globe. In addition, sedentary lifestyle and faulty dietary habits are augmenting the prevalence of this condition. As a result, constantly rising patient population is propelling the growth of this market.

Presently, no condition specific treatment is available. As a result, the treatments that are available are symptom specific. Polycystic ovary syndrome therapy mainly includes lifestyle modification that involves a balanced diet, exercise; and drugs such as oral contraceptives, insulin-sensitizing agents, anti-obesity agents, and antidepressants. In cases where patients do not respond effectively to any drug therapy, surgical procedures such as ovarian wedge resection and laparoscopic ovarian drilling are recommended.

Insulin-sensitizing agents are the largest segment. Various products such as Glucophage XR (Metformin) and other products containing Troglitazone, Rosiglitazone, and Pioglitazone are sold widely. In PCOS, metabolic dysfunction may lead to excess androgen secretion, which may affect insulin secretion and may ultimately increase the risk of diabetes. Thus, insulin-sensitizing agents play an important role in the therapeutics as they lower insulin levels and lead to a decrease in production of ovarian androgen as well as balance hormone levels.

Oral Contraceptive Pills (OCPs) segment is expected to be the fastest growing segment. Commercially available oral contraceptive products mainly include Ethinyl Estradiol, Medroxyprogesterone Acetate, and Drospirenone. These OCPs are used for treatment of irregular or absent menstrual cycle, severe menstrual pain, Premenstrual Syndrome (PMS), and acne, which are common symptoms of Polycystic ovary syndrom. As a result, demand for OCPs segment is expected to increase at the fastest rate during the forecast period.     

Surgery Insights

When drug therapy proves to be ineffective, surgery is recommended for treatment. The most common surgeries performed for treatment of PCOS include ovarian wedge resection and laparoscopic drilling of ovaries. Some of the other procedures that are performed are oophorectomy, hysterectomy, and cyst aspiration.

Ovarian wedge resection involves removal of a part of ovary, which may help regulate the menstrual cycle and promote ovulation. Physicians strongly recommend not undergoing wedge resection due the risk of scarring on ovaries. In addition, associated risks, such as pain in lower abdomen, bleeding, scarring on reproductive organs or damage to them, and infection, are making drug therapies a preferred option over surgical procedures for treatment of PCOS.

Regional Insights

North America is the most developed market followed by Europe. Rising incidence of obesity and overweight is resulting in an increase in number of people suffering from PCOS, which is one of the key factors contributing to market growth in North America. Moreover, increasing awareness about benefits of regular checkup is leading to an increase in number of new cases being diagnosed each year in this region. 

The U.S. is leading the overall North America market with the largest revenue share. The large population suffering from PCOS in this country is primarily driving growth of this market. Moreover, presence of major market players, such as Merck, Abbott, and BMS, in the U.S. is anticipated to contribute significantly in the revenue generation of the country.

In Asia Pacific, China and India together account for the largest population base. Thus, the presence of a large target patient pool creates significant growth opportunities for PCOS treatment market in the region. Governments of these countries are focusing on controlling the growing prevalence of PCOS by conducting programs that support diagnosis & therapeutics of this syndrome and the required lifestyle modification. These programs are leading to an increase in awareness about PCOS and its associated risks such as development of insulin resistance, obesity, and in some cases infertility. These factors are expected to drive the Asia Pacific market in the near future.

Competitive Insights

Some of the key players in the market are AstraZeneca, Bayer AG, Merck KGaA, Abbott, Sanofi, Pfizer, Inc., Bristol-Myer Squibb Company, and Novartis AG. Emerging players in the market include Teva Pharmaceutical Industries Limited and Ferring Pharmaceuticals, Inc., which are expected to hold a significant share of the market over the forecast period. Key players adopt strategies such as collaborations and mergers & acquisitions and enter into partnerships to strengthen their position in the market. 

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the polycystic ovarian syndrome treatment market on the basis of drug class, surgery and region:

• Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)

  • Oral Contraceptives

  • Antiandrogens

  • Insulin-sensitizing Agent

  • Antidepressant

  • Anti-obesity

• Surgery Outlook (Revenue, USD Billion; 2014 - 2025)

  • Ovarian Wedge Resection

  • Laparoscopic Ovarian Drilling

• Regional Outlook (Revenue, USD Billion; 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Mexico

    • Brazil

  • MEA

    • South Africa